Signal active
Bio
Dr. Healy is a General Partner at Sofinnova Ventures. Dr. Healy has over 15 years of experience in biomedical research and development. He joined Sofinnova Ventures as a General Partner in 2000. Dr. Healy was an early investor and board member of Cellective (acquired by MedImmune), CoTherix (acquired by Actelion), Novacea (Nasdaq: NOVC), and InterMune (Nasdaq: ITMN). He also serves on the boards of directors of several private companies.
In the pharmaceutical industry, he held a manufacturing position at Bayer Pharmaceuticals (Miles) and helped guide the discovery group at ISTA Pharmaceuticals prior to its initial public offering. Dr. Healy authored or co-authored numerous research articles and reviews, including three papers published in Nature. He began his private equity career at Sanderling.
Dr. Healy earned B.A.s in Molecular Biology and Scandinavian Studies from the University of California at Berkeley, where he graduated with Distinction in General Scholarship, Honors, and received a Departmental Citation. Dr. Healy received his M.D. from Stanford University’s School of Medicine through the Medical Scientist Training Program, and earned his Ph.D. in Immunology from Stanford University, where he was a Beckman Scholar and received a bursary award from the Novartis Foundation. Dr. Healy teaches a course on entrepreneurship at Stanford University, and is an active member of the BIO-NVCA Working Group.
Location
Menlo Park, California, United States, North America
Social
Primary Organization
1974
300
76
118
11-50
Financial Services, Venture Capital, Finance
Jobs history
3
Seaport Therapeutics
Board of Director
Invalid date - Current
Chairman of the Board
2024 - Current
Rapport Therapeutics
Board Member
Invalid date - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
James Healy is the General Partner & President at Sofinnova Investments, based in United States, North America. With a background in Financial Services, James Healy has a rich history of leadership and innovation. James Healy studied BS Molecular Biology, Scandinavian @ University of California Berkeley. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
25
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Dec 29, 2022 | ArriVent Biopharma | Series B - ArriVent Biopharma | Sofinnova Investments | 155.0M |
Aug 23, 2023 | Rapport Therapeutics | Series B - Rapport Therapeutics | Sofinnova Investments | 150.0M |
Feb 13, 2024 | - | Series D - BioAge Labs | Sofinnova Investments | 170.0M |
Apr 09, 2024 | Seaport Therapeutics | Series A - Seaport Therapeutics | Sofinnova Investments | 100.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.